Tarian Pharma are grateful to have been selected as a winner of the 2022 iLAB competition on July 4th, 2022.
This National contest is organised by the Ministry of Higher Education, Research and Innovation and is implemented by BPI France. From an initial selection of 396 dossiers in the domains of digital, engineering and health innovation, a rigorous assessment process recognized 78 start-up enterprises which will get financial support in addition to a label that is acknowledged by investors.
This prestigious price and associated funding arrived at an opportune time for Tarian Pharma as the company is entering into the critical phase of clinical development. In 2023, our lead drug product, TAR-0520, which is intended for the prevention of adverse cutaneous effects of cancer treatments, will advance into Phase 1 and 2 clinical programs.